Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | CASP7 | P55210 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | RGS12 | O14924 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CASP1 | P29466 | 1/20 | 1.00 |
| ▸ | GNAI1 | P63096 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | NOS1 | P29475 | 7/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | PAH | P00439 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sepiapterin SCHEMBL20374908 | 1.00 | HSD17B10 (1.00) | HSD17B10CASP7KDM4EMAPTBLM | |
| Sepiapterin SCHEMBL8288993 | 1.00 | HSD17B10 (1.00) | HSD17B10CASP7KDM4EMAPTBLM | |
| SCHEMBL19734024 | 0.91 | CASP7 (0.83) | HSD17B10CASP7KDM4EMAPTBLM | |
| SCHEMBL20374992 | 0.80 | CASP7 (0.67) | HSD17B10CASP7KDM4EMAPTBLM | |
| Sepiapterin SCHEMBL258399 | 0.79 | CASP7 (0.65) | HSD17B10CASP7KDM4EMAPTBLM | |
| Sepiapterin SCHEMBL27081912 | 0.79 | CASP7 (0.65) | HSD17B10CASP7KDM4EMAPTBLM | |
| SCHEMBL258405 | 0.77 | HSD17B10 (0.63) | HSD17B10CASP7KDM4EMAPTBLM | |
| SCHEMBL21009255 | 0.77 | HSD17B10 (0.63) | HSD17B10CASP7KDM4EMAPTBLM | |
| SCHEMBL31026287 | 0.77 | HSD17B10 (0.63) | HSD17B10CASP7KDM4EMAPTBLM | |
| SCHEMBL29365035 | 0.77 | HSD17B10 (0.63) | HSD17B10CASP7KDM4EMAPTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240122931-A1 | METHODS FOR TREATING COVID-19 WITH SEPIAPTERIN | PTC THERAPEUTICS MP INC (US) | 2024-04-18 | — | — | US | disclosed |
| US-20240115572-A1 | METHODS FOR TREATING GLIOBLASTOMAS WITH SEPIAPTERIN | VIRGINIA COMMONWEALTH UNIVERSITY | 2024-04-11 | — | — | US | disclosed |
| EP-4291196-A1 | METHODS FOR TREATING COVID-19 WITH SEPIAPTERIN | PTC Therapeutics MP, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| EP-4291190-A1 | METHODS FOR TREATING GLIOBLASTOMAS WITH SEPIAPTERIN | PTC Therapeutics MP, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| US-11773097-B2 | Polymorphs of sepiapterin and salts thereof | PTC THERAPEUTICS MP, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773097-B2 | Polymorphs of sepiapterin and salts thereof | PTC THERAPEUTICS MP, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| CN-113727733-B | Triamterene or nolatrexed for treating phenylketonuria | 索姆创新生物技术公司 | 2023-01-24 | — | — | CN | disclosed |
| WO-2022173834-A1 | METHODS FOR TREATING GLIOBLASTOMAS WITH SEPIAPTERIN | PTC THERAPEUTICS MP, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| WO-2022173823-A1 | METHODS FOR TREATING COVID-19 WITH SEPIAPTERIN | PTC THERAPEUTICS MP, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| US-11173158-B2 | Medicinal agent and beverage/food for preventing cerebral dysfunction and improving same | PTC THERAPEUTICS MP, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20150119574-A1 | METHOD FOR PRODUCING SEPIAPTERIN AND TETRAHYDROLACTOYLPTERIN | SHIRATORI PHARMACEUTICAL CO., LTD. (JP) | 2015-04-30 | — | — | US | disclosed |
| EP-2848619-A1 | METHOD FOR PRODUCING SEPIAPTERIN AND TETRAHYDROLACTOYLPTERIN | Shiratori Pharmaceutical Co., Ltd. (JP) | 2015-03-18 | — | — | EP | disclosed |
| EP-2848619-A1 | METHOD FOR PRODUCING SEPIAPTERIN AND TETRAHYDROLACTOYLPTERIN | Shiratori Pharmaceutical Co., Ltd. (JP) | 2015-03-18 | — | — | EP | disclosed |
| US-20130197000-A1 | DRUG AND FOOD/DRINK FOR PREVENTING OR IMPROVING CEREBRAL DYSFUNCTION | NIHON UNIVERSITY (JP) | 2013-08-01 | — | — | US | disclosed |
| EP-2562176-A1 | MEDICINAL AGENT AND BEVERAGE/FOOD FOR PREVENTING CEREBRAL DYSFUNCTION AND IMPROVING SAME | Nihon University (JP) | 2013-02-27 | — | — | EP | disclosed |
| US-20110144117-A1 | Pharmaceutical Dosage Form Containing Tetrahydrobiopterin | ORPHA SWISS GMBH (CH) | 2011-06-16 | — | — | US | disclosed |
| US-20110144117-A1 | Pharmaceutical Dosage Form Containing Tetrahydrobiopterin | ORPHA SWISS GMBH (CH) | 2011-06-16 | — | — | US | disclosed |
| WO-2010017570-A2 | PHARMACEUTICAL FORM COMPRISING TETRAHYDROBIOPTERIN | ORPHA SWISS GMBH (CH) | 2010-02-18 | — | — | WO | disclosed |
| US-20080221111-A1 | Roflumilast and sepiapterin; (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin; prevention, treatment of respiratory diseases | NYCOMED GMBH (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221111-A1 | Roflumilast and sepiapterin; (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin; prevention, treatment of respiratory diseases | NYCOMED GMBH (DE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119574-A1 | METHOD FOR PRODUCING SEPIAPTERIN AND TETRAHYDROLACTOYLPTERIN | SPR, HPN, RNPEP | HSD17B10 348/4885CASP7 1605/4885KDM4E 4148/4885 |
| US-11773097-B2 | Polymorphs of sepiapterin and salts thereof | SPR, PAH, SORD | HSD17B10 251/4885CASP7 1781/4885KDM4E 1231/4885 |
| US-20080221111-A1 | Roflumilast and sepiapterin; (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin; prevention, treatment of respiratory diseases | SPR, PAH, QDPR | HSD17B10 419/4885CASP7 1166/4885KDM4E 527/4885 |
| US-20110144117-A1 | Pharmaceutical Dosage Form Containing Tetrahydrobiopterin | QDPR, MTHFD2, DHODH | HSD17B10 273/4885CASP7 2361/4885KDM4E 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.